drugset
drugset / Trial / NCT00688896

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

NCT00688896 ↗

Phase 2 Completed 155 enrolled Akros Pharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.

Timeline

Start
2002-06
Primary completion
2003-04
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalcetrapib Small molecule 300 mg Oral
Subject Dalcetrapib Small molecule 600 mg Oral
Comparator Pravastatin Small molecule 40 mg Oral

Indications

hyperlipidemia